HIV drugs approved for use in NHS Wales
Two HIV medicines are among the drugs approved for use on the NHS in Wales in November 2008
Two HIV medicines are among the drugs approved for use on the NHS in Wales in November 2008.
The All Wales Medicines Strategy Group recommends raltegravir (Isentress) as an option in treatment-experienced adults and fixed-dose abacavir and lamivudine (Kivexa) is endorsed as a treatment for adults and adolescents from 12 years of age. Each medicine should be used in accordance with British HIV Association guidance.
A third medicine — rufinamide (Inovelon) — is recommended as an adjunctive therapy in patients four years and older with Lennox-Gastaut syndrome when other adjunctive treatments have proved sub-optimal or have not been tolerated.
Four drugs failed to be approved for use because the case for clinical or cost effectiveness was not proved. These are:
- Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture
- Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients or for treatment of allograft rejection resistant to other immunosuppressants in adult patients
- Icatibant acetate (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema in adults with C1-esterase-inhibitor deficiency
- Stiripentol (Diacomit) for the treatment of severe myoclonic epilepsy in infancy
Citation: The Pharmaceutical Journal URI: 10040579
Recommended from Pharmaceutical Press